Outcomes20

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 20 of 20

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Response Rate (ORR)	Up to 22 months	Evaluable population of patients who received at least 1 dose of therapy. No statistical analysis is performed.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Duration of Response	Up to 22 months		Months	MEDIAN
SECONDARY	Number of Participants With Adverse Events	Adverse events were collected from first dose of study treatment up to 30 days after last dose of treatment, up to 21 months (number of treatment given ranged from 1 cycle to 30 cycles).	All enrolled patients are included. No statistical analysis is performed.	participants	NUMBER
SECONDARY	Overall Survival (OS)	Up to 41 months	All enrolled patients are included. Statistical analysis was not performed.	Months	MEDIAN
SECONDARY	Progression Free Survival (PFS)	Up to 23 months	All patients were included in the analysis. Statistical analysis was not performed.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarker With Overall Response Rate - HPV Status	Up to 22 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected for the non-small cell lung cancer cohort.	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Association of Biomarker With Overall Response Rate - P16 Status	Up to 22 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Association of Biomarkers With Overall Response Rate - EphrinB2 Status	Up to 22 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Association of Biomarkers With Overall Response Rate - PD-L1 Status	Up to 22 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Association of Biomarkers With Overall Response Rate - EphrinB2 Positive/HPV-negative	Up to 22 months	Only the Head and Neck cancer cohort is being reported. No statistical analysis performed. No specimens were collected in the non-small cell lung cancer cohort.	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Association of Biomarkers With Overall Survival (OS) - HPV Status	Up to 34 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Overall Survival (OS) - P16 Status	Up to 34 months	Only the Head and Neck cancer cohort is being reported. 10 participants were P16-positive, 15 participants were P16-negative, for a total of 25 participants. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Overall Survival (OS) - EphrinB2	Up to 24 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Overall Survival (OS) - PD-L1 Status	Up to 34 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Overall Survival (OS) - EphrinB2 Positive/HPV-negative	Up to 34 months	Only the Head and Neck cancer cohort is being reported. No statistical analysis performed. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Progression Free Survival (PFS) - HPV Status	Up to 11 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Progression Free Survival (PFS) - P16 Status	Up to 11 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Progression Free Survival (PFS) - EphrinB2 Status	Up to 11 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Progression Free Survival (PFS) - PD-L1 Status	Up to 11 months	Only the Head and Neck cancer cohort is being reported. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Association of Biomarkers With Progression Free Survival (PFS) - EphrinB2 Positive/HPV-negative	Up to 11 months	Only the Head and Neck cancer cohort is being reported. No statistical analysis performed. No specimens were collected in the non-small cell lung cancer cohort.	Months	MEDIAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03049618/outcomes

API reference For AI assistants